Home > Insider Trading > Filing (0001485003-23-000109)

Filing Details

Accession Number:: 0001485003-23-000109
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-06 20:45:37
Reporting Period:: 2023-03-02

Accepted Time:: 2023-03-06 20:45:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1485003	Sesen Bio Inc.	SESN	Pharmaceutical Preparations (2834)	262025616

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1773277	C Glen Macdonald	C/O Sesen Bio, Inc. Suite 1800 Cambridge MA 02142	Chief Technology Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-03-02	76,247	$0.59	206,751	No	4	S	Direct
Common Stock	Acquisiton	2023-03-02	183,317	$0.59	390,068	No	4	M	Direct
Common Stock	Disposition	2023-03-02	60,237	$0.59	329,831	No	4	S	Direct
Common Stock	Acquisiton	2023-03-02	102,975	$0.59	432,806	No	4	M	Direct
Common Stock	Disposition	2023-03-02	33,888	$0.59	398,918	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Footnotes

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above.
Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 1, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.